Chae Moon Hong1, Byeong-Cheol Ahn1, So-Young Choi2, Do-Hoon Kim1, Sang-Woo Lee1, Tae-Geon Kwon2, Jaetae Lee1. 1. Department of Nuclear Medicine, School of Medicine and Hospital, Kyungpook National University, 50 Samduk-dong 2-ga, Jung Gu, Daegu, South Korea 700-721. 2. Department of Oral & Maxillofacial Surgery, School of Dentistry, Kyungpook National University, Daegu, South Korea.
Abstract
PURPOSE: Bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ) is a well-known serious complication of BP treatment. This study was undertaken to evaluate the diagnostic usefulness of three-phase bone scintigraphy in patients with BRONJ. METHODS: Forty-one patients (48 lesions) with clinically proven BRONJ (2 males, 39 females, age 74.3 ± 6.7 years) underwent Tc-99 m HDP bone scintigraphy. Visual interpretation and semiquantitative analysis of uptakes using lesion-to-contralateral uptake ratios during the blood pool phase (BUR) and during the osseous phase (OUR) were performed, and relations were sought between these and various clinical parameters. RESULTS: Three-phase bone scintigraphy showed increased perfusion and blood pooling in 21 (63.6 %) and 27 (81.8 %) of 33 lesions, respectively. The osseous phase was positive for 45 (93.8 %) of the 48 lesions. Of the four inflammatory clinical parameters of BRONJ [pus discharge, pain, swelling, and erythrocyte sedimentation rate (ESR)], patients with three or more parameters had more positive findings in vascular and blood pool phase images (p = 0.033, p = 0.027). By semiquantitative analysis, patients with a positive ESR had statistically higher BUR and OUR (both p < 0.001). Higher stage BRONJ lesions had higher OUR than lower stage lesions (p = 0.003). In addition, bone scintigraphy revealed three clinically covert BRONJ lesions without bone exposure, and four patients were up-staged based on bone scintigraphy. CONCLUSIONS: Bone scintigraphy provides a relatively sensitive means of detecting BRONJ, so it was helpful for accurate BRONJ staging. Furthermore, increased uptakes in vascular and blood pool phases of three-phase bone scintigraphy were related to the inflammatory activity of BRONJ.
PURPOSE:Bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ) is a well-known serious complication of BP treatment. This study was undertaken to evaluate the diagnostic usefulness of three-phase bone scintigraphy in patients with BRONJ. METHODS: Forty-one patients (48 lesions) with clinically proven BRONJ (2 males, 39 females, age 74.3 ± 6.7 years) underwent Tc-99 m HDP bone scintigraphy. Visual interpretation and semiquantitative analysis of uptakes using lesion-to-contralateral uptake ratios during the blood pool phase (BUR) and during the osseous phase (OUR) were performed, and relations were sought between these and various clinical parameters. RESULTS: Three-phase bone scintigraphy showed increased perfusion and blood pooling in 21 (63.6 %) and 27 (81.8 %) of 33 lesions, respectively. The osseous phase was positive for 45 (93.8 %) of the 48 lesions. Of the four inflammatory clinical parameters of BRONJ [pus discharge, pain, swelling, and erythrocyte sedimentation rate (ESR)], patients with three or more parameters had more positive findings in vascular and blood pool phase images (p = 0.033, p = 0.027). By semiquantitative analysis, patients with a positive ESR had statistically higher BUR and OUR (both p < 0.001). Higher stage BRONJ lesions had higher OUR than lower stage lesions (p = 0.003). In addition, bone scintigraphy revealed three clinically covert BRONJ lesions without bone exposure, and four patients were up-staged based on bone scintigraphy. CONCLUSIONS: Bone scintigraphy provides a relatively sensitive means of detecting BRONJ, so it was helpful for accurate BRONJ staging. Furthermore, increased uptakes in vascular and blood pool phases of three-phase bone scintigraphy were related to the inflammatory activity of BRONJ.
Entities:
Keywords:
Bisphosphonate; Jaws; Osteonecrosis; Three-phase bone scintigraphy
Authors: Salvatore L Ruggiero; Thomas B Dodson; Leon A Assael; Regina Landesberg; Robert E Marx; Bhoomi Mehrotra Journal: J Oral Maxillofac Surg Date: 2009-05 Impact factor: 1.895
Authors: P Maurer; T Sandulescu; M S Kriwalsky; A Rashad; S Hollstein; I Stricker; F Hölzle; M Kunkel Journal: Int J Oral Maxillofac Surg Date: 2010-12-15 Impact factor: 2.789
Authors: Felice S O'Ryan; Sam Khoury; Wendy Liao; Myo M Han; Rita L Hui; David Baer; Daniel Martin; Donald Liberty; Joan C Lo Journal: J Oral Maxillofac Surg Date: 2009-07 Impact factor: 1.895
Authors: Noopur Raje; Sook-Bin Woo; Karen Hande; Jeffrey T Yap; Paul G Richardson; Sonia Vallet; Nathaniel Treister; Teru Hideshima; Niall Sheehy; Shweta Chhetri; Brendan Connell; Wanling Xie; Yu-Tzu Tai; Agnieszka Szot-Barnes; Mei Tian; Robert L Schlossman; Edie Weller; Nikhil C Munshi; Annick D Van Den Abbeele; Kenneth C Anderson Journal: Clin Cancer Res Date: 2008-04-15 Impact factor: 12.531
Authors: Christian Thomas; Magdalena Spanidis; Christina Engel; Frederik C Roos; Sebastian Frees; Andreas Neisius; Christian Hampel; Peter Rubenwolf; Joachim W Thüroff; Christian Walter; Matthias Miederer Journal: Clin Oral Investig Date: 2015-08-26 Impact factor: 3.573
Authors: Christian Thomas; Georg Bartsch; Christian Walter; Hendrik Borgmann; Maximilian Peter Brandt; Thomas Höfner; Axel Haferkamp; Igor Tsaur Journal: Dent J (Basel) Date: 2016-08-19
Authors: Christian Philipp Reinert; Christina Pfannenberg; Sergios Gatidis; Christian la Fougère; Konstantin Nikolaou; Sebastian Hoefert Journal: Front Oncol Date: 2021-07-01 Impact factor: 6.244